key: cord-1013824-41palmyc
authors: Asem, N.; Hassany, M.; Taema, K.; Masoud, H.; Elassal, G.; Kamal, E.; Amin, W.; Abdelbary, A.; Abdel-Baki, A.; Zaky, S.; Abdalmohsen, A.; Ibrahim, H.; Elnady, M.; Mohamed, A.; Attia, E.; Zaid, H.
title: Demographic and clinical features associated with in-hospital mortality in Egyptian COVID-19 patients: A retrospective cohort study
date: 2021-03-25
journal: nan
DOI: 10.1101/2021.03.22.21253577
sha: a12ed305aba263b5189e541ddb5bc42e460569fb
doc_id: 1013824
cord_uid: 41palmyc

Introduction: Since the worldwide emergence of the COVID-19, several protocols were used by different healthcare organisations. We evaluated in this study the demographic and clinical characteristics of COVID-19 disease in Egyptian population with special consideration for its mortality predictors. Methodology: 8162 participants (mean age 48.7 years,54.5% males) with RT-PCR positive COVID-19 were included. The electronic medical records were reviewed for demographic, clinical, laboratory, and radiologic features. The primary outcome was the in-hospital mortality rate. Results: The in-hospital mortality was 11.2%. There was a statistically significant strong association of in-hospital mortality with age >60 years old (OR:4.7; 95% CI 4.1-5.4;p<0.001), diabetes mellitus (OR:4.6; 95% CI 3.99-5.32;p<0.001), hypertension (OR:3.9; 95% CI 3.4-4.5;p<0.001), coronary artery disease (OR:2.7; 95% CI 2.2-3.2;p<0.001), chronic obstructive pulmonary disease (OR:2.1; 95% CI 1.7-2.5;p<0.001), chronic kidney disease (OR:4.8; 95% CI 3.9-5.9;p<0.001), malignancy (OR:3.7; 95% CI 2.3-5.75;p<0.001), neutrophil-lymphocyte ratio >3.1 (OR:6.4; 95% CI 4.4-9.5;P< 0.001), and ground glass opacities (GGOs) in CT chest (OR:3.5; 95% CI 2.84-4.4;P<0.001), respectively. There was a statistically significant moderate association of in-hospital mortality with male gender (OR:1.6; 95% CI 1.38-1.83;p<0.001) and smoking (OR:1.6; 95% CI 1.3-1.9;p<0.001). GGOs was reported as the most common CT finding (occurred in 73.1% of the study participants). Conclusions: This multicenter, retrospective study ascertained the higher in-hospital mortality rate in Egyptian COVID-19 patients with different comorbidities.

A pneumonia outbreak caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been identified at the end of 2019 in Wuhan city, China.

The pneumonia outbreak spread rapidly crossing international boundaries and was declared as a global pandemic by the WHO on March 11 th , 2020 [1, 2] . The disease is designated COVID-19, which stands for coronavirus disease 2019 [3] .

Acute COVID-19 pneumonia induced acute respiratory distress syndrome (ARDS) is a potential significant concern for morbidity and mortality, besides other induced lifethreatening complications that include, but are not limited to, arrhythmias, acute cardiac injury, and shock. Critical illness mainly occurs in elderly individuals, especially with underlying comorbidities as diabetes mellitus (DM), hypertension, coronary artery disease (CAD), malignancy, chronic obstructive pulmonary disease (COPD), and/or chronic kidney disease (CKD) [4] . Laboratory parameters associated with severe disease and related to disease progression include ferritin and D-Dimer [5] .

On 15/02/2020, Egypt declared the first reported COVID-19 patient [6] which increased to a range of 710-5241 patients by March 31 st [7] . In February 2020, the Egyptian Ministry of Health designated a scientific committee for steering the national clinical COVID-19 management protocol. Due to lack of evidence for the effectiveness of any antiviral therapy

Retrospective data from the study participants' standardized electronic medical records were collected and coded, and the data were analyzed using the statistical package for the social sciences software (SPSS version 25) . A quantitative (continuous) variable was considered parametrically (normally) distributed if the z-value of skewness and kurtosis was between -1.96 and +1.96 [15] and the Shapiro-Wilk's test had a p-value > 0.05 [16] . We found that our quantitative (continuous) variables were parametrically (normally) distributed. Accordingly, quantitative (continuous) data were expressed as means and standard deviations.

Parametrically distributed quantitative (continuous) variables were compared with the Independent two-tailed t-test. Qualitative (categorical) data were expressed as proportions.

Qualitative (categorical) variables were compared with Chi-Square Test (x 2 ). The probability of in-hospital mortality was expressed as odds ratio (OR). The confidence interval was set to 95% (95 % CI) and the margin of error accepted was set to 5%. Any comparison considered statistically significant was at P-value ≤ 0.05.

We reviewed the standardized electronic medical records of 8162 patients with RT-PCR positive COVID-19 disease from 17 hospitals in one country from March 20 th till May 30 th , 2020. The study group was disproportionate with regards to the demographic data, comorbidities, disease severity, and baseline laboratory findings ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

A total of 7247 study participants survived their hospital course, while 915 study participants died with an in-hospital mortality rate of 11.2% (95% CI 10.5% -11.9%). The highest mortality rate was in the severe/critical subgroup (646 study participants) (46.7%; 95% CI 44.0% -49.3%) compared to the mild subgroup (68 study participants) (1.6%; 95% CI 1.2% -2.0%) and the moderate subgroup (201 study participants) (7.7%; 95% CI 6.7% -8.7%), respectively (P< 0.001). The in-hospital mortality was 23.5% in patients >60 years old compared to 6.1% in those <65 years old (P < 0.001). The in-hospital mortality was reported is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (145/690), and 31.9% (100/313) of patients with one, two, and three or more comorbid conditions, respectively (P < 0.001) (Figure 2 ).

There was a statistically significant strong association of in-hospital mortality with age >60 years old (OR: 4.7; 95% CI 4.1-5.4), DM (OR: 4.6; 95% CI 3.99-5.32), hypertension (OR:

3.9; 95% CI 3.4-4.5), CAD (OR: 2.7; 95% CI 2.2-3.2), COPD (OR: 2.1; 95% CI 1.7-2.5), chronic liver disease (OR: 2.5; 95% CI 2.04-3.2), CKD (OR: 4.8; 95% CI 3.9-5.9), and malignancy (OR: 3.7; 95% CI 2.3-5.75), respectively (P< 0.001). There was a statistically significant moderate association of in-hospital mortality with male gender (OR: 1.6; 95% CI 1.38-1.83) and smoking (OR: 1.6; 95% CI 1.3-1.9), respectively (P< 0.001) ( Table 2) .

Apart from the occurrence of bleeding, the presence of any of the complications, or the presence of any of the CT findings was associated with a significantly higher risk for mortality (Figures 3 and 4 ).

The lower serum hemoglobin level, higher total leucocytic count, lower lymphocytic count, higher alanine transaminase (ALT) and aspartate transaminase (AST), higher C-reactive protein (CRP), higher serum creatinine and ferritin levels, lower serum albumin, and higher admission random blood sugar were shown to be significantly associated with higher inhospital mortality ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

The negative RT-PCR conversion rate was 86.2% by the 12 th day of treatment and 95.9% after the 18 th day of treatment with a peak of 15.2% on the 3 rd day of treatment ( Figure 5 ).

With the emergence of the first COVID-19 patient in Egypt on 15/02/2020 [6] , the Egyptian Fever and cough were reported in 69.8% and 67.5% of our study participants. In another study [17] , fever was reported in 94% of patients and cough in 79% of patients. These symptoms of presentation were not, however, associated with mortality [17].

Our study's overall in-hospital mortality was 11.2 %. According to the baseline severity of illness identified on presentation to the healthcare facilities, the mortality rates were 1.6%, 7.7%, and 46.7% for mild, moderate, and severe/critical cases, respectively. A retrospective cohort study of 191 hospitalized COVID-19 patients in Wuhan, China from December 29 th , 2019 till January 31 st , 2020 reported the death of 54 patients with a mortality rate of 28.3 %.

However, they didn't report the stratification of mortality as per disease severity. In a meta- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint In addition to the baseline severity of illness identified on hospital admission and the occurrence of complications during hospital course, the clinical and laboratory features associated with in-hospital mortality were age >60 years old, male gender, COPD, DM, hypertension, CAD, chronic liver disease, malignancy, CKD, neutrophilia, lymphopenia, high CRP, ALT and AST levels, and higher admission serum creatinine and ferritin levels. The

Odds Ratio reported in our study suggested a strong association of the in-hospital mortality with age >60 years old, DM, hypertension, chronic liver disease, CKD, malignancy, septic shock, myocarditis, ARDS, DIC, acute liver dysfunction, lymphadenopathy, pleural effusion, and CT finding of multilobar involvement.

Several studies revealed higher mortality rates with advancing age [18,20,21]. A study by Juan Berenguer involving 4035 patients in Spain showed a higher mortality rate with increasing age >60 years old (OR: 7.5; 95% CI 6-9.4) compared to (OR: 4.7; 95% CI 4. 1-5.4) reported in our study [22] . This might be secondary to comorbidities linked to advancing age and decreased immune response. CKD, malignancy and liver cirrhosis were reported to be strongly associated with mortality in COVID-19 patients with an OR for CKD ranging from 3.6 in many studies to 9.4 in one meta-analysis study, and OR for malignancy and liver cirrhosis of 2.3 to 2.8, respectively [19, 22] . In addition to their significant impact on mortality, the higher incidence rates of hypertension (33.4%) and DM (30.9%) add to their importance as measures of association with mortality in COVID-19 patients. Hypertension and DM were reported as the most common comorbidities that impact mortality in many studies [19, 22] . In our study, hypertension and DM caused 3.9 and 4.6 folds increase in the . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Leukocytosis, lymphopenia, high serum CRP, ALT, AST, and ferritin levels reported in our study were associated with higher mortality rates. Similarly, Berenguer et al reported significantly higher mortality with higher neutrophil count and lower lymphocyte count. They reported also higher CRP, ALT, and AST in non-survivors [22] . The association of higher mortality rates with leukocytosis, neutrophilia, high CRP, and high ferritin levels might be secondary to the dysregulated immune response in COVID-19 patients or superadded secondary infections [25] . The higher mortality rate associated with lymphopenia might represent a dysregulated cellular immune response characterizing COVID-19 [26].

Combining both, the higher NLR was associated with higher mortality. We reported an inhospital mortality rate of 26% in patients with NLR >3.1 compared to 5.2% in patients with NLR <3.1. Similar results were reported in earlier studies [27] . The elevated serum creatinine, ALT, AST, and low albumin levels might explain the higher mortality reported in chronic liver disease and CKD. We reported a non-significant tendency for higher D-dimer levels in non-survivors. Contrary to this, a significant tendency for higher D-dimer levels in non-survivors was reported by many other investigators [17,28] representing the coagulopathy pattern in COVID-19.

The most common CT finding was the GGOs which were reported in 73.1% of patients. Its' presence showed a more than 3 folds increase in the odds of death in our cohort of study participants. Despite their lower incidence of occurrence, the presence of consolidation, pleural effusion, or lymphadenopathy was associated with a significantly higher mortality is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Our study showed negative RT-PCR conversion rates of 15.2% by the 3 rd day of treatment 

Our study has strengths. There were on-site visits by the scientific steering committee members to verify compliance with the Egyptian COVID-19 management protocol. The incidence rates of the clinical efficacy outcomes were estimated, information was collected on all relevant potential confounders, recall bias was prevented, and the causal inference was strengthened. On the other hand, the study has limitations. There were inadequate reporting and analysis of our interventions data so, couldn't specify the pivotal medication which played an essential role in the management of the COVID-19 disease. Updates to the . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Egyptian COVID-19 management protocol were not applied to the current study. The documentation process for laboratory investigations in the quarantine hospitals was inefficient in the early phase of the study with subsequent missing data for the continuous laboratory variables. Despite the study limitations, we collected complete data for the categorical variables.

This multicenter, retrospective cohort study investigated the demographic, clinical, laboratory, and radiologic features associated with in-hospital mortality in the Egyptian COVID-19 patient population and confirmed the higher in-hospital mortality rate in patients with comorbidities. Double-blinded randomized controlled trials are warranted to make an inference about the treatment effect of the different management elements.

This research received funding from the Egyptian Ministry of Health and Population.

The authors have no conflicts of interest to disclose.

1.

WHO Director-General's (2020) opening remarks at the media briefing on COVID-19 -11 March 2020. Available: https://www.who.int/dg/speeches/detail/who-directorgeneral-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Tables   Table 1: The demographic data, comorbidities, disease severity, and baseline laboratory findings of the study population is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 25, 2021. ; https://doi.org/10.1101/2021.03.22.21253577 doi: medRxiv preprint

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Characteristics of and Important Lessons from the

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

WHO (2020) Coronavirus disease 2019 (COVID-19) Situation Report -26

Estimation of COVID-19 burden in Egypt

% (2.2 % -2.8 %) INR

D-dimer (micg/mL)